Table 2 Type and frequency of KRAS mutations according to smoking status in 80 patients with NSCLC
From: Proportion and clinical features of never-smokers with non-small cell lung cancer
KRAS mutation | Nucleotide substitution | Amino acid substitution | Never-smokers [cases (%)] | Ever-smokers [cases (%)] | Total [cases (%)] |
|---|---|---|---|---|---|
Transversion | GGT>TGT | Gly12Cys | 6 (22.2) | 22 (41.5) | 28 (35.0) |
GGT>GTT | Gly12Val | 7 (25.9) | 12 (22.6) | 19 (23.8) | |
GGT>GCT | Gly12Ala | 2 (7.4) | 3 (5.7) | 5 (6.3) | |
GGT>TTT | Gly12Phe | 0 | 1 (1.9) | 1 (1.3) | |
Transition | GGT>GAT | Gly12Asp | 11 (40.7) | 11 (20.8) | 22 (27.5) |
GGT>AGT | Gly12Ser | 0 | 2 (3.8) | 2 (2.5) | |
GGC>GAC | Gly13Asp | 0 | 2 (3.8) | 2 (2.5) | |
CAG>CGG | Gln22Arg | 1 (3.7) | 0 | 1 (1.3) | |
Total | 27 | 53 | 80 |